Most exacerbations of asthma in childhood can be proven to be associated with viral infections. In a study by Johnston et al1 using the polymerase chain reaction (PCR) and culture, viruses were detected in 80% of episodes of wheeze or reduced peak flow in 9–11-year-olds with asthma. Rhinoviruses accounted for 61% of the viruses detected, coronaviruses 16%, influenza 9%, parainfluenza 9%, and RSV 5%.
Rhinoviruses have been detected in lower-airway cells during experimental rhinovirus infection.2 The mechanism by which viruses cause bronchospasm is not yet understood, but is likely to involve cytokine production in response to viral replication in the lower airway.
RSV infection, although detected in only 5% of asthma episodes in the study by Johnston et al,1 is known to be a potent cause of wheezing, particularly in infancy. It has been shown that RSV infections in infancy are associated with a TH2-like cytokine response (see page 663) in the upper airway, whether or not the infant is atopic.4 TH2 cytokine patterns are known to be associated with viral immunopathology and allergic-type responses, in contrast to TH1 cytokine patterns, which are classically associated with viral elimination. It has also been shown that levels of at least one cytokine (IL-2) are similar in upper and lower respiratory tract secretions during RSV infection, suggesting that upper respiratory tract levels can be used as an indicator of lower respiratory tract levels.5 Interestingly, the nasal cytokine responses to rhinoviruses are of the TH1 type,4 as are the responses to other viruses (except RSV). This could explain the propensity for RSV to cause wheezing, but not the association between other respiratory viruses and wheezing.
There is controversy as to whether RSV infection in infancy can cause asthma, or merely uncovers pre-existing asthma. The evidence to date favours the latter.6,7 The incidence of later asthma is higher compared with controls for infants whose RSV bronchiolitis is severe enough to require hospitalisation,6,7 but not for infants who develop milder RSV bronchiolitis that can be managed at home.8 A recent study has suggested that RSV bronchiolitis in infancy is associated with an increased risk of recurrent wheeze up to six years of age, but that the risk decreases markedly after that age.9 No association was found between RSV lower respiratory tract infection and atopy.
Chlamydia pneumoniae causes 5%–20% of community-acquired pneumonia in children and adults.10 C. pneumoniae is not associated with asthma in children, but serological studies have suggested a possible association with new-onset asthma in adults and with chronic stable asthma.11 Serological studies in adults with asthma suggest a possible role for C. pneumoniae in the pathogenesis of severe asthma.11 A trial of roxithromycin in adults with asthma and serological evidence of recent Chlamydia infection showed only short-term benefit,12 and this may have been due to the known anti-inflammatory effects of macrolides13 rather than to any antibacterial effect.
Mycoplasma pneumoniae classically causes dry cough and fever in school-aged children (≥ 5 years old).14 Wheeze is not a classical symptom of Mycoplasma infection, although it may occur, and Mycoplasma is an uncommon cause of exacerbations of asthma.1,15 M. pneumoniae occurs in outbreaks every three to five years, and is relatively uncommon between these epidemics (see Box).14
The diagnosis of Mycoplasma infection is problematic. Culture is slow and insensitive. Serum IgM is a sensitive indicator of infection, but, because it persists for up to 12 months, is not specific. A single high complement fixation test (CFT) result, which detects IgG and IgM, has the same problem as IgM, while a rising CFT is specific but only 50% sensitive. The use of macrolide antibiotics should be reserved for children in whom there is a high suspicion of atypical pneumonia — they should certainly not be used routinely to treat acute asthma.
There is accumulating evidence that frequent respiratory infections in infancy, particularly bacterial infections, may protect against atopy.16 This may explain the low rate of atopic asthma in Indigenous children and adults found in one study,17 although recent data from Western Australia and Queensland suggest that asthma may be more common in Indigenous people than the earlier study reported.
- David Isaacs1
- Preeti Joshi2
- Department of Immunology and Infectious Diseases, The Children's Hospital at Westmead, and University of Sydney, NSW.
- 1. Johnston SL, Pattemore PK, Sanderson S, et al. Community study of role of viral exacerbations of asthma in 9–11 year old children. BMJ 1995; 310: 1225-1229.
- 2. Gern JE, Galagan DM, Jarjour NN, et al. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am J Respir Crit Care Med 1997; 155: 1159-1161.
- 3. Anderson GP. Therapeutic prospects for early asthma. Med J Aust 2002; 177 Suppl Sep 16: 66-69. <eMJA full text>
- 4. Joshi P. A cohort study of cytokines and atopy [PhD thesis]. University of Sydney, 2001.
- 5. Joshi P, Kakakios A, Jayasekera J, Isaacs D. A comparison of IL-2 levels in nasopharyngeal and endotracheal aspirates of babies with respiratory syncytial viral bronchiolitis. J Allergy Clin Immunol 1998; 102: 618-620.
- 6. Wang S-Z, Forsyth RD. Asthma and respiratory syncytial virus infection in infancy: is there a link? Clin Exp Allergy 1998; 28: 927-935.
- 7. Welliver RC. RSV and chronic asthma. Lancet 1995; 346: 789-790.
- 8. McConnochie KM, Roghmann KJ. Predicting clinically significant lower respiratory tract illness in childhood following mild bronchiolitis. Am J Dis Child 1985; 139: 625-631.
- 9. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999; 354: 541-545.
- 10. Hammerschlag MR. Chlamydia pneumoniae and the lung. Eur Respir J 2000; 16: 1001-1007.
- 11. Johnston SL. Is Chlamydia pneumoniae important in asthma? The first controlled trial of therapy leaves the question unanswered. Am J Respir Crit Care Med 2001; 164: 513-514.
- 12. Black PN, Francesco B, Jenkins R, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001; 164: 536-541.
- 13. Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000; 6: 594-598.
- 14. File TM Jr, Tan JS, Plouffe JF. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am 1998; 12: 569-592.
- 15. Micillo E, Bianco A, D'Auria D, et al. Respiratory infections and asthma. Allergy 2000; 55(Supp 61): 42-45.
- 16. Von Mutius E, Illi S, Hirsch T, et al. Frequency of infections and risk of asthma, atopy and airway hyperresponsiveness in children. Eur Respir J 1999; 14: 4-11.
- 17. Peat JK, Veale A. Impact and aetiology of respiratory infections, asthma and airway disease in Australian Aborigines. J Paediatr Child Health 2001; 37: 108-112.
Abstract
What we knowWhat we need to know